This program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for veterans with CLL.
This activity aims to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to optimally integrate the use of currently available therapies for their patients with CLL.
Upon completion of this activity, participants should be able to:
Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
Develop treatment plans to address unique clinical challenges based on the available evidence and the recommendations outlined in recognized guidelines to optimize outcomes for veterans with CLL/SLL
Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles among agents with a similar molecular target used to treat CLL/SLL
Evaluate the evolving role of noncovalent BTK inhibitors, measurable/minimal residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy in the therapeutic strategy for veterans with CLL
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Solomon Graf, MD
Division of Medical Oncology
University of Washington Medicine
Clinical Research Division
Fred Hutchinson Cancer Center
Solomon Graf, MD: researcher: Acerta Pharma, BeiGene, GlaxoSmithKline, MorphoSys, TG Therapeutics.
Jeffrey P. Sharman, MD
Willamette Valley Cancer Institute
Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.
The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.
Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.
Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 01, 2023, through November 30, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-312-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.